Discovery Life Sciences to acquire Gentest business from Corning Incorporated

Learn More

New: First of its kind Proteomics Consortium

Learn More

We Are The Biospecimen and Biomarker Specialists™

The world’s largest biospecimen inventory

Discovery is a global market leader in biospecimen analysis, procurement, and distribution for pharmaceutical, biotechnology, and diagnostics industries.

World-class, integrated service lab workflows

Preserve precious samples using Discovery’s optimized and integrated IHC, Cell, and Genomic Services.

Play

Grounded in a Science at Your Service™ Attitude

The world’s largest biospecimen inventory and procurement network with preeminent multi-omic service laboratories to accelerate precision medicine programs

Image

Over 10 Million Research-Quality Samples

Discovery has the largest repository of biosamples and the global logistical systems to acquire, biostore, and ship them most efficiently.

Image

HudsonAlpha Discovery™

HudsonAlpha Discovery™ provides comprehensive genomic services to support R&D, translational and pre-clinical drug and diagnostic programs.

Image

Pathology-Guided IHC Services

Discovery’s IHC and histopathology services help you understand your target biomarkers at every stage of research and clinical development.

Image

Flow Cytometry + 10x Libraries + Cell Culture + More

Advanced flow cytometry services for deep characterization of biospecimens, premium human primary immune cell isolations and custom cell processing services.

Order inventory online at the

Discovery BIOstore Logo
Previous

Blood Products

Explore the full spectrum of blood-based biospecimens including fresh whole blood, double-spun plasma, serum, buffy coat, cord blood and bone marrow.

Learn More

FFPE

Explore the world’s largest commercial repository of diseased and benign FFPE tissue.

Learn More

DTCs

Explore DTC inventory from the team who were the first to validate cryopreserved tissue dissociations as a viable alternative to fresh tissue.

Learn More

Immune Cell Isolates

Multiple primary immune cell isolations from healthy donors including MNCs, T cells, B cells, NK cells, dendritic cells, monocytes, macrophages, etc. with consistent purity, viability and characterization via NGS and flow cytometry

Learn More

Hepatocytes

High-quality, primary, cryopreserved hepatocytes, pre-screened and characterized for plateability, viability, metabolic activity, CYP induction, and transporter efflux activity.

Learn More

BMMCs

Explore Discovery’s Diseased and Healthy Bone Marrow Mononuclear Cells (BMMCs) with Flow Cytometric Immunophenotypic Data Available.

Learn More

Biofluids

Explore the full spectrum of non-blood biofluid biospecimens including urine, saliva, aspirate, cerebrospinal fluid (CSF), oral swab, bronchoalveolar lavage (BAL), nasal fluid, synovial fluid, sputum and other biofluid biospecimens

Learn More

Matched Sets

Explore matched donor biospecimen sets across various biospecimen formats.

Learn More
Next

The Latest

Featured Case Studies

Previous

Establishing HER2 As A Companion Diagnostic Biomarker For The Treatment Of Breast & Gastric Cancers

The prognostic, diagnostic and predictive value of the HER2 biomarker has been established for breast, gastric, and gastro-esophageal junction cancers. Over the past two decades, therapies such as Trastuzumab, Lapatinib and Trastuzumab-duocarmazine have been developed to treat these cancers, but their use and efficacy depend on accurate classification of the HER2 status of the tumor. Differences in HER2 expression among these cancers and tissue types requires expert analysis to score and interpret, and Discovery’s Global Tissue Biomarker Services Europe has led the field in establishing methodological guidelines to meet this need. The Discovery Biomarker Academy offers global pathology biomarker training services with experts instructing on cutting-edge platforms and current methods for IHC and in situ hybridization. Discovery’s Global Tissue Biomarker Services have supported assay development, validation and global clinical trial testing by providing expeditious and high-quality results, which are crucial to the success of drug and companion diagnostic development programs and are fit for any stage of research and development.

Download Case Study

IHC Assay That Advanced Development Of Pembrolizumab

Our prototype assay’s expert development resulted in an assay with wide dynamic range, high precision and reproducible results, laying the foundation for the successful 22C3 PD-L1 companion diagnostic assay widely utilized today to select patients eligible for treatment with the anti-PD-1 immunotherapy pembrolizumab.

Download Case Study

Custom Sourcing for a 30 Patient, Matched Monocytes and Pan T-cells Study

The client in this case study is a recognized and respected researcher in the hematological oncology discovery group of a major biopharma company. The researcher has been investigating interactions of novel therapies within the microenvironments of multiple hematological malignancies. Discovery Life Sciences has been a human biologics partner to this discovery group for over 5 years, providing diseased bone marrow and peripheral blood samples, but had not previously provided any healthy isolated immune cells. The discovery group typically sourced isolated cells from two well-known vendors, but has often had challenges with accrual timelines as well as the post-thaw quality and viability of the cells.

Download Case Study
Next

The Latest

News and Events

Most Recent

Paper icon

Discovery Life Sciences To Acquire Gentest Business From Corning Incorporated

Biospecimen Leader to Combine Gentest with Recent IVAL Acquisition to Create Leading In Vitro Drug Metabolism Services Offering
Read More

News

Paper icon

Cryopreserved Leukopaks: Addressing the Viability Myth

Recent publications, including a landmark paper from Novartis¹, demonstrate the viability and utility of cryopreserved leukopaks, ...
Read More

News

Paper icon

Addressing the Achilles Heel of T-Cell Therapy

Cryopreserved leukopaks eliminate the constraints imposed by a reliance on fresh human cells for T-cell therapies. ...
Read More

To propel your projects with The Power of Discovery.™

Contact Us Today

Let us know about your project!

Image